Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 10;6(9):FSO618.
doi: 10.2144/fsoa-2020-0087.

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Laura Diluvio  1 , Arianna Piccolo  1 , Francesco Marasco  2 , Laura Vollono  1 , Caterina Lanna  1 , Barbara Chiaramonte  3 , Cinzia Niolu  2 , Elena Campione  1 , Luca Bianchi  1
Affiliations

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Laura Diluvio et al. Future Sci OA. .

Abstract

Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab.

Materials & methods: A total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.

Results: The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.

Conclusion: Omalizumab allowed an improvement of urticaria and mental comorbidities.

Keywords: CSU; DLQI; H1-anti-histamine; HADS; Hospital Anxiety and Depression Scale; UAS7; anxiety; chronic spontaneous urticaria; depression; omalizumab; psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. The case-control comparison of Hospital Anxiety and Depression Scale-Anxiety, Hospital Anxiety and Depression Scale-Depression, CRP, erythrocyte sedimentation rate, Urticaria Activity Score for 7 days and Dermatology Life Quality Index mean values at baseline (T0) and after 6 months of treatment with omalizumab (T1).
DLQI: Dermatology Life Quality Index; ESR: Erythrocyte sedimentation rate; HADS: Hospital Anxiety and Depression Scale; HADS-A: HADS-anxiety; HADS-D: HADS-depression; UAS7: Urticaria Activity Score for 7 days.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Maurer M, Weller K, Bindslev-Jensen C. et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 66(3), 317–330 (2011). - PubMed

    2. •• Extensively explains chronic spontaneous urticaria (CSU), from ethiopathogenesis to therapy.

    1. Lapi F, Cassano N, Pegoraro V. et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br. J. Dermatol. 174(5), 996–1004 (2016). - PubMed
    1. Weldon D. Quality of life in patients with urticaria and angioedema: assessing burden of disease. Allergy Asthma Proc. 35(1), 4–9 (2014). - PubMed
    1. Zuberbier T, Aberer W, Asero R. et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 69(7), 868–887 (2014). - PubMed

    2. • Outlines the current urticaria guidelines.

    1. Weller K, Groffik A, Magerl M. et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 67(10), 1289–1298 (2012). - PubMed